MTATP6P26

Across TCGA pan-cancer cohorts, MTATP6P26 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of MTATP6P26’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MTATP6P26 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MTATP6P26 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.

HNSC, STAD, and KIRC are the cancer types where MTATP6P26 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTATP6P26 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.105	<.001	7	view →
STAD	Male	All	+0.359	<.001	5	view →
KIRC	Male	II,III,IV	+0.099	.001	5	view →
CHOL	All	All	+0.356	.001	3	view →
COAD	All	All	+0.170	.007	3	view →
BRCA	Female	All	−0.116	.030	2	view →
ESCA	All	All	+0.891	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

MTATP6P26–HNSC

Open the HNSC breakdown →